PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.034, up 21.43%, on 356,757 volume with 46 trades. The average volume for the last 60 days is 594,885 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies
• CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Posts Update on Scorpion Venom-Derived Peptide Program
• PreveCeutical Provides Update on Second Phase of Scorpion Venom-Derived Peptide Program

ChineseInvestors.com (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

Premier financial information company ChineseInvestors.com, Inc. (OTCQB: CIIX) is committed to empowering Chinese-speaking investors in the United States and China by providing market analysis and educational cryptocurrency information. To view the full article, visit: http://ccw.fm/PCdf5. Also today, CryptoCurrencyWire released a report on the company detailing how CIIX’s CEO, Warren Wang recently predicted that the company would perform well and provide ‘good times’ for its shareholders in 2019 and 2020 as its programs develop advances. Advances including a comprehensive series of bitcoin services, such as the planned creation of an international bitcoin ATM network, and its core business of subscriptions and media relations.

Founded in 1999, ChineseInvestors.com (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.539, up 18.59%, on 701,247 volume with 318 trades. The average volume for the last 60 days is 68,132 and the stock's 52-week low/high is $0.365/$1.58.

Recent News

• CryptoNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Targets Massive Consumer Group with Cryptocurrency Education Broadcasts
• ChineseInvestors.com, Inc. (CIIX) CEO Remains Bullish on Bitcoin Pricing Due to Supply and Demand
• ChineseInvestors.com, Inc. (CIIX) Eyes International Expansion with Bitcoin ATMs, Cryptocurrency Courses

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

As the U.S. Securities and Exchange Commission weighs several applications seeking to establish an exchange-traded investment fund (ETF) for the bitcoin cryptocurrency, Virtual Crypto Technologies Inc. (OTCQB: VRCP) is applauding the signs that regulatory sentiment in the United States appears to be shifting in favor of cryptocurrencies, paving the way for anticipated mass adoption of bitcoin (Crypto: BTC) and other cryptocurrencies.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

• Downloadable NetoBit Trader app link and contact forms for more information
• MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
• Improved security utilizing https certificates to protect personal information and site integrity
• Media room with downloadable product brochures, corporate presentations and other relevant content
• Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
• Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.1275, up 15.80%, on 4,830 volume with 10 trades. The average volume for the last 60 days is 32,449 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

• Virtual Crypto Technologies Inc. (VRCP) Enthused by Signs of Changing SEC Sentiment toward Bitcoin ETFs
• CryptoNewsBreaks – Virtual Crypto Technologies Inc. (VRCP) Aims to Increase Cryptocurrency Accessibility
• Virtual Crypto Technologies Inc. (VRCP) Leads the Way toward Widespread Cryptocurrency Adoption as US Regulatory Sentiment Shifts

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

CannabisNewsAudio announces the Audio Press Release (APR) titled “$1 Trillion Global Health and Wellness Sector Presents Growing Opportunities for Cannabidiol Companies,” featuring Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF). To hear the CannabisNewsAudio version, visit http://cnw.fm/hlJ0U. To read the full editorial, visit http://cnw.fm/t5Qvw. Also today, CannabisNewsWire released a report on the company detailing how PHVAF earlier this week, signed an exclusive national agreement with Natural Specialty Sales (“NSS”), an Acosta company. Per the agreement, Phivida’s OKI brand of premium CBD products will be the exclusive CBD-infused beverage brand and health supplements products represented by NSS, giving the company access to over 2,400 retail locations in a $4.1 billion market. To view the corporate video, visit http://cnw.fm/Kn3Pq.

Headquartered in Vancouver, Canada, with operations offices in southern California, Phivida Holdings Inc. (CSE: VIDA) (OTCQX: OTCQX) is a premium food and beverage company that develops CBD-infused functional foods, beverages and supplements poised for global distribution. All products in the Phivida label are infused with organic, hemp-derived cannabinoids into a variety of premium foods, beverages and clinical products for everyday health. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s motto – “Celebrating Health and Wellness, in Harmony™” – underscores Phivida’s mission to lead the alternative health care sector as the benchmark standard in premium CBD-infused functional beverages and tinctures. To execute this goal, Phivida is taking advantage of positive legislative developments in the United States and has defined an elevated national route-to-market strategy across the U.S. where small regional distributors will be now be replaced with large national distributors.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who as Phivida’s chief commercial officer is tasked with driving new sales revenue growth.

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF), the company’s strong balance sheet carries CAD$15.7 million with no debt or loans with less than 60 million shares outstanding and the company is now well-capitalized to fun major mainstream distribution with a solid structure poised for long-term growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

Encapsulated CBD is infused into functional beverages, food and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health and wellness conditions. Phivida tests every product for microbials, heavy metals, pesticides, residual solvents, terpenes, and potency to guarantee less than 0.3 percent THC (tetrahydrocannabinol, the chemical compound in cannabis responsible for a euphoric high) is present.

Regulations

Federally legal under the 2014 Farm Bill, CBD from Hemp Oil is a rapid growth market across the USA. When derived from marijuana, CBD remains a schedule one controlled substances, giving hemp derived CBD oil infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the USA Industrial Hemp laws to an agricultural commodity status and effectively removed hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the US CBD-Hemp sector. In February 2018, the Supreme Court preceded over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp, and the legality of industrial hemp. In the final ruling the Supreme Court unequivocally determined that – when produced domestically under the Farm Bill – hemp (and its derivatives) are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA) giving the Farm Bill primary jurisdiction over the governance of the CBD-Hemp Oil industry in the USA.

The DEA further conceded it does not “seek to control cannabinoids,” and that only marijuana derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g. US Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreation cannabis – with edibles to be added in 2019. The bill will officially become law as of October 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

3 Wholly Owned Subsidiaries

• Phivida Organics Inc. offers professional-grade, wholesale, whole plant hemp oil extracts made from 100-percent certified organic hemp stalk. Phivida’s hemp oil extracts are CO2-extracted under quality assurance/clinical standards and are third-party lab tested to assure only pharmaceutical grade, cGMP certified, full-spectrum products are produced and available for sale. Phivida Organics produces hemp oil extracts that deliver nano-encapsulated cannabinoids in water soluble formulations designed to be absorbed up to 10 times faster than other oils, providing up to 400 percent bioavailability. Phivida Hemp Oil Vida+ extract products are available now online at www.Phivida.com.
• Phivida Nutrition blends the best of nature into CBD-infused lifestyle branded beverages including a variety of CBD infused iced teas and CBD infused flavored waters.
• Phivida Enhanced – Under the VIDA brand, CBD-infused tinctures, capsules and other supplement products are distributed to alternative health care clinics across the USA.

WeedMD-Phivida

Phivida has signed a binding letter of intent to joint venture WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on cannabis-infused beverages. The new joint-venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario, Canada. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets.

Management from both WeedMD and Phivida are collaborating on design and engineering strategies and site evaluations on a 610,000-square-foot, state-of-the art facility in Strathroy for the development of CanBev. As an emerging certified food grade production plant, the Strathroy facility is an ideal location and comes is equipped with extensive production infrastructure, including 50,000 sq. ft. of food production and packaging area, cold storage, loading docks, and adequate space to expand for future growth.

Strategic Agreements

Phivida Organics has also entered into an agreement to carry out a pharmacokinetic (PK) study on its hemp-derived, nanoencapsulated CBD with Artelo Biosciences Inc. at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England. The study will test encapsulated-CBD on healthy volunteers and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations developed by Phivida Organics.

Phivida has also activated distribution agreements with Asayake Inc. to become one of the first federally approved CBD-infused food and supplement brands in Japan. With first mover status achieved, Phivida now markets to an underserved, yet highly informed population of 127 million patients and practitioners. The supplement market in Japan is estimated at US$10 billion with the overall functional foods market at US$21 billion. The Asia-Pacific region is the fastest growing market for natural plant-based supplements. Phivida now plans to prepare a formal application to Japan’s Consumer Affairs Agency to register the company’s CBD-infused functional food and beverage products for approval under the country’s Food with Functional Claims regime. The functional beverage market in Japan is estimated at US$10.35 billion with a CAGR of 2.5 percent (2015-2025).

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.69, up 11.06%, on 15,192 volume with 18 trades. The average volume for the last 60 days is 25,800 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

• CannabisNewsAudio Announces Audio Press Release (APR) on Phivida Holdings Inc. Cultivating Opportunity in a Rising CBD Market
• NetworkNewsBreaks – Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Releases Corporate Video Detailing Exclusive National Agreement with Natural Specialty Sales
• Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is “One to Watch”

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Vertically integrated cannabis company Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) recently revealed its plans to spinoff its Canadian assets to attain the full value of its resources in both the US and Canada. The proposal, which would create a new entity listing on the Toronto Stock Exchange (TSX) and Nasdaq, will leave Sunniva’s U.S. assets to trade on the Canadian Stock Exchange, the company announced in a recent press release (http://cnw.fm/pBkO0).” To view the full article, visit: http://cnw.fm/lJ1mw.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $4.43, up 0.91%, on 28,678 volume with 43 trades. The average volume for the last 60 days is 41,846 and the stock's 52-week low/high is $4.14/$16.00.

Recent News

• NetworkNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Set to Reach Full Value of Assets via Planned Spinoff
• CannabisNewsBreaks – Cannabis Strategic Ventures, Inc. (NUGS) Engages NetworkNewsWire for Corporate Communications Solutions
• Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Subsidiary Inks Another Supply Contract for Upcoming Cannabis Crop

Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC: NUGS) is engaged in supporting entrepreneurial growth within the burgeoning legal cannabis market. To view the full article, visit: http://nnw.fm/Koi4F.

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $2.02, up 1.00%, on 9,922 volume with 18 trades. The average volume for the last 60 days is 34,626 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

• NetworkNewsBreaks – Why Cannabis Strategic Ventures, Inc. (NUGS) is “One to Watch”
• Coverage Initiated for Cannabis Strategic Ventures (OTC: NUGS) via NetworkNewsWire
• Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Signs Cannabis Extraction Deal with Cannabis Strategic Ventures (OTC: NUGS)

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

Leading Canadian cannabis company ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently announced that it is changing its name to VIVO Cannabis Inc. to reflect the company’s evolution, purpose and direction. To view the full press release, visit: http://cnw.fm/zlHe4.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” ABcann Global CEO Barry Fishman said.

ABcann Global owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

ABcann has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by ABcann’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting ABcann’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

ABcann’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with ABcann’s philosophy of quality and innovation.

ABcann’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, ABcann also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

ABcann Global (ABCCF), closed the day's trading session at $1.00, even for the day, on 207,150 volume with 183 trades. The average volume for the last 60 days is 209,571 and the stock's 52-week low/high is $0.65/$3.2929.

Recent News

• NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Changes Company Name to VIVO Cannabis
• ABcann Introduces Lumina, a Cannabis Brand Focused on Wellness
• NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Enters Definitive Agreement to Acquire Canna Farms Ltd.

DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

Diverse holdings company DPW Holdings (NYSE American: DPW) this morning announced that Microphase Corporation, a division of the company’s Coolisys Technologies, Inc. subsidiary, has secured a $2.0 million addition to its previously announced $2.1 million contract award from a first-tier U.S. government defense contractor. To view the full press release, visit: http://ccw.fm/D8kby.

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

• The highest efficiency and highest density power converters and inverters
• Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
• Very high-frequency filters
• Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

• Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
• Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
• Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
• Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
• Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

• Achieve compounded annual revenue growth of 25-35%
• Achieve compounded annual net Income growth of 5%
• Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.465, off by 0.43%, on 864,448 volume with 1,096 trades. The average volume for the last 60 days is 2,043,442 and the stock's 52-week low/high is $0.4205/$5.95.

Recent News

• DPW Holdings’ Microphase Corporation Secures $2.0 Million Supplemental Order from Top-Tier U.S. Defense Contractor
• CryptoNewsBreaks – Why DPW Holdings, Inc. (NYSE American: DPW) is “One to Watch”
• NetworkNewsBreaks – Why DPW Holdings, Inc. (NYSE American: DPW) is “One to Watch”

Zenosense, Inc. (OTCQB: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

With cardiovascular disease being the leading cause of death globally for both men and women, and one in four Americans dying of heart disease every year (http://nnw.fm/dcq1M), the need for more accurate and faster cardiac diagnostic methods is more than evident. Health care technology company Zenosense, Inc. (OTCQB: ZENO) aims to address this issue through the development of transformational medical diagnostic technology that can offer true laboratory-level accuracy of results at the point of care.

Zenosense, Inc. (OTCQB: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.385, off by 0.77%, on 47,075 volume with 22 trades. The average volume for the last 60 days is 271,314 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

• Zenosense, Inc. (ZENO) Aims to Revolutionize Cardiac Diagnostics Market
• NetworkNewsBreaks – Zenosense, Inc. (ZENO) Continues to Reach Key Milestones
• NetworkNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac Device Proves Potential to Saves Lives through Early Detection

GTX Corp (OTC: GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXO).

GPS technology-focused holding company GTX Corp (OTC: GTXO) has created an assortment of tracking technologies that deliver comfort and safety to consumers. To view the full article, visit: http://nnw.fm/FQj9z.

GTX Corp (OTC: GTXO) designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business.  Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

• Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
• Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
• Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
• E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
• GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXO), closed the day's trading session at $0.0989, off by 1.10%, on 123,311 volume with 25 trades. The average volume for the last 60 days is 1,674 and the stock's 52-week low/high is $0.0825/$0.6675.

Recent News

• NetworkNewsBreaks – GTX Corp (GTXO) Delivers Diverse Suite of Wearable Tracking Devices
• GTX Corp’s (GTXOD) GPS SmartSole in UK Trials through National Health Service
• GTX Corp (GTXOD) Expanding Sales into Retail Channels

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update on Net Element, Inc. (NASDAQ: NETE). The note is available here: NETE August 2018 Update Note.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
• Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
• Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $6.94, off by 1.07%, on 53,925 volume with 269 trades. The average volume for the last 60 days is 130,541 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

• SeeThruEquity Issues Update on Net Element, Inc.
• Net Element, Inc. (NASDAQ: NETE) Fights Fraud with Disposable Credit Card Numbers on its Netevia Platform
• Net Element Announces Acquisition of Recurring Cash Flow Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented delivery mechanism improves the bioabsorption and bioavailability of ingestible substances while also improving taste and smell. For companies entering into or already established in the cannabis industry, this is good news. The bitterness of cannabis when creating consumable products can now be reduced and even eliminated.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.695, off by 4.78%, on 110,901 volume with 156 trades. The average volume for the last 60 days is 237,710 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products
• Lexaria’s DehydraTECH Triples Bioavailability of CBD in Human Trial -- CFN Media
• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products